WallStreetZen

AnalystsKeay Nakae
Keay Nakae's Stock Forecasts

Analyst Ranking
Top 1%
#23 out of 3474 analysts
Average Return
+201.01%
Win Rate
41%11 out of 27
Risk vs Reward
Poor
Good

Keay Nakae's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Ocugen IncOCGN
+5,554.71%$0.22$12.61
2020-06-02 -
2021-02-09
Strong Buy
CareCloud IncMTBC
+104.17%$2.40$4.90
2017-11-13 -
2018-11-14
Strong Buy
Arrowhead Pharmaceuticals IncARWR
+62.51%$19.39$31.51
2018-09-05 -
2019-09-06
Strong Buy
Mesoblast LtdMESO
+62.36%$16.10$6.06
2020-12-03 -
2021-10-27
Strong Sell
Forte Biosciences IncFBRX
+33.60%$5.06$3.36
2021-09-02 -
2021-09-20
Strong Sell

Keay Nakae's Stock Coverage

Name / Ticker# of RatingsRatingPrice TargetUpside/DownsideActionDate
BiomX IncPHGE
1Strong Buy$16.00+601.75%Maintains
9 days ago
Forte Biosciences IncFBRX
2Hold$3.50+32.08%Upgrades
a month ago
Mesoblast LtdMESO
2Strong Sell$6.50+7.26%Maintains
2 months ago
Dicerna Pharmaceuticals IncDRNA
2Strong Buy$28.00+30.11%Maintains
3 months ago
ProQR Therapeutics NVPRQR
1Strong Buy$18.00+139.36%Maintains
3 months ago
Arrowhead Pharmaceuticals IncARWR
3Strong Buy$94.00+45.76%Maintains
3 months ago
Seres Therapeutics IncMCRB
1Strong Buy$16.00+158.48%Maintains
3 months ago
Femasys IncFEMY
1Strong Buy$25.00+256.13%Initiates Coverage On
4 months ago
Axcella Health IncAXLA
1Strong Buy$10.00+215.46%Maintains
5 months ago
Emergent BioSolutions IncEBS
5Strong Buy$92.00+90.75%Maintains
6 months ago
Ocugen IncOCGN
2Hold$13.00+35.28%Downgrades
9 months ago
Sonnet BioTherapeutics Holdings IncSONN
2Strong Buy$8.00N/AMaintains
a year ago
Oncocyte CorpOCX
2Hold$2.00N/ADowngrades
a year ago
NeuBase Therapeutics IncNBSE
2Strong Buy$18.00N/AMaintains
2 years ago
Arbutus Biopharma CorpABUS
1Strong Buy$5.00N/AUpgrades
2 years ago
Caladrius Biosciences IncCLBS
1Strong Buy$7.00N/AMaintains
4 years ago
CareCloud IncMTBC
1Strong Buy$2.75N/AMaintains
4 years ago
Biocept IncBIOC
1Strong Buy$2.50N/AInitiates Coverage On
4 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.